NDAINJECTIONINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRECEF (ceforanide) is an injectable second-generation cephalosporin antibiotic approved in 1984 for bacterial infections. It is administered via injection and works by inhibiting bacterial cell wall synthesis. The drug treats a range of gram-positive and gram-negative bacterial infections across surgical and medical indications.
LOE Approaching
Product is in late-stage lifecycle with minimal competitive pressure at 30%, indicating a small and likely consolidating commercial team focused on defending market share.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRECEF offers stability and operational expertise in a legacy brand with established market presence, but minimal growth trajectory or career acceleration potential. Roles focus on margin protection, institutional relationships, and compliance rather than innovation or commercial expansion.
Brand ManagerAccount Manager
Worked on PRECEF at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.